Davern Capital Partners, LP
NY, NY · CIK 2003147 · 13F filing filed 2026-05-14
SEC-registered investment adviser since 2025 · limited partnership
- Assets managed$715.1m
- Staff4 · 3 in investment roles
- Main clients (by assets)Sovereign wealth funds 92%, Private funds 8%
- Private funds1 (1 hedge) · $55.1m gross assets
- Main officeNew York, NY
- Websitedaverncapital.com
- Form ADV · 2026-03-27SEC adviser record
- Legal entityDAVERN CAPITAL PARTNERS, LP (US)
$364.5m
reported value
+17.9% vs Q4 2025
17positions
80.7%in top 10
4 new
7 added
6 reduced
1 sold out
vs Q4 2025
Holdings, Q1 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| PFIZER INC PFE | $44.8m12.28% | Reduced -448.3k |
| REGENERON PHARMACEUTICALS REGN | $34.6m9.50% | Reduced -7.6k |
| INSMED INC INSM | $29.9m8.19% | New |
| IONIS PHARMACEUTICALS INC IONS | $29.1m7.97% | Added +148.4k |
| NATERA INC NTRA | $28.8m7.90% | Added +65.3k |
| BIONTECH SE BNTX | $27.1m7.44% | Reduced -66.2k |
| ARGENX SE ARGX | $25.6m7.02% | Reduced -640 |
| ELI LILLY & CO LLY | $25.1m6.88% | Added +19.0k |
| ROYALTY PHARMA PLC RPRX | $24.9m6.84% | Reduced -320.6k |
| ROIVANT SCIENCES LTD ROIV | $24.2m6.64% | Reduced -154.9k |
| LEGEND BIOTECH CORP LEGN | $23.8m6.52% | Added +258.1k |
| MINERALYS THERAPEUTICS INC MLYS | $12.1m3.32% | Added +236.5k |
| ABIVAX SA ABVX | $8.7m2.39% | Added +29.6k |
| GENERATE BIOMEDICINES INC GENB | $7.4m2.03% | New |
| PROCEPT BIOROBOTICS CORP PRCT | $6.5m1.79% | New |
| STRUCTURE THERAPEUTICS INC GPCR | $6.1m1.67% | New |
| VIRIDIAN THERAPEUTICS INC VRDN | $5.9m1.62% | Added +40.8k |
Sold out since Q4 2025
| Security | Value then |
|---|---|
| CG ONCOLOGY INC CGON | $6.7m162.0k shares |